Recommendations for Transgender and Gender Nonconforming Adolescents and Young Adults With Inflammatory Bowel Disease
- 23 December 2020
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 72 (5) , 752-755
Abstract
Transgender and gender nonconforming (TGNC) individuals have a different gender identity than the sex they were assigned at birth. Despite an increase in provider awareness of TGNC health over the past decade, no original research or societal guidelines exist on TGNC patients with inflammatory bowel disease (IBD). We review TGNC IBD cases in the University of California, San Francisco (UCSF) Pediatric IBD Program and in the literature. We then provide some recommendations for the provision of high‐quality care to the TGNC IBD population, divided into 3 categories: medications, anatomy, and mental health.Keywords
This publication has 15 references indexed in Scilit:
- Endocrinology of Transgender MedicineEndocrine Reviews, 2018
- Systematic review with meta‐analysis: anxiety and depression in children and adolescents with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2018
- Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel DiseaseCanadian Journal of Gastroenterology and Hepatology, 2017
- Prolonged P-Wave and QT Dispersion in Children with Inflammatory Bowel Disease in RemissionBioMed Research International, 2017
- Neovaginal Sparing in a Transgender Woman With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2016
- Inflammatory Bowel Disease in Children and AdolescentsJAMA Pediatrics, 2015
- Risks associated with the therapeutic use of fluoroquinolonesExpert Opinion on Drug Safety, 2013
- Youth with Special Health Care Needs: Transition to Adult Health Care ServicesMaternal and Child Health Journal, 2012
- Biological Drug Treatment of Rheumatoid Arthritis and Spondyloarthritis: Effects on QT Interval and QT DispersionThe Journal of Rheumatology, 2011
- The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelixJournal of Clinical Oncology, 2004